Investors bought shares of BioTelemetry Inc. (NASDAQ:BEAT) on weakness during trading hours on Friday. $47.78 million flowed into the stock on the tick-up and $2.80 million flowed out of the stock on the tick-down, for a money net flow of $44.98 million into the stock. Of all equities tracked, BioTelemetry had the 27th highest net in-flow for the day. BioTelemetry traded down ($0.06) for the day and closed at $19.02

Separately, Zacks Investment Research cut shares of BioTelemetry from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 26th.

The firm has a market cap of $530.54 million and a P/E ratio of 48.15. The firm has a 50 day moving average price of $16.89 and a 200 day moving average price of $13.75.

A number of institutional investors have modified their holdings of BEAT. Dimensional Fund Advisors LP raised its position in shares of BioTelemetry by 8.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,317,266 shares of the company’s stock valued at $15,386,000 after buying an additional 98,737 shares during the last quarter. 1492 Capital Management LLC raised its position in shares of BioTelemetry by 11.4% in the fourth quarter. 1492 Capital Management LLC now owns 321,761 shares of the company’s stock valued at $3,758,000 after buying an additional 32,932 shares during the last quarter. Royce & Associates LLC raised its position in shares of BioTelemetry by 102.2% in the fourth quarter. Royce & Associates LLC now owns 606,700 shares of the company’s stock valued at $7,086,000 after buying an additional 306,700 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of BioTelemetry by 13.6% in the fourth quarter. Wells Fargo & Company MN now owns 994,163 shares of the company’s stock valued at $11,612,000 after buying an additional 119,328 shares during the last quarter. Finally, Gabelli Funds LLC acquired a new position in shares of BioTelemetry during the fourth quarter valued at $1,190,000.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.